Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 17Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Cholangiocarcinoma 2Biliary Tract Neoplasms 2Pancreatic Ductal Adenocarcinoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Lymphoma, Follicular 1Leukemia 1IDH1 Mutation Myeloid Neoplasms 1Hematologic Neoplasms 1Glioma 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1AML 1

Interventions

Cyclophosphamide 176Rituximab 164fludarabine phosphate 97Peripheral Blood Stem Cell Transplantation 95Filgrastim 73Etoposide 67Radiotherapy 63Mycophenolic Acid 62Whole-Body Irradiation 58Tacrolimus 49Melphalan 49Cyclosporine 49Busulfan 47Lenalidomide 45Antilymphocyte Serum 39Vincristine 37Prednisone 37Cytarabine 37fludarabine 35Methotrexate 33Carmustine 32obinutuzumab 31Doxorubicin 30Bendamustine Hydrochloride 30Methylprednisolone 27ibritumomab tiuxetan 25Cord Blood Stem Cell Transplantation 25sargramostim 24Bortezomib 24Granulocyte Colony-Stimulating Factor 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Follicular × ivosidenib × Clear all
NCT04278781 2026-04-23

AG-120 in People With IDH1 Mutant Chondrosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
6 enrolled
LymphoidSarcoma

Chondrosarcoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡